Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 257 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Actos (Pioglitazone) Clear all
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Effect of Thiazolidinediones on Human Bone

NCT00927355
View directory record Official record
Conditions
Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 4, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional

GALLANT 6 Tesaglitazar vs. Pioglitazone

NCT00214565
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Galida
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Altoona, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 4, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

NCT05582707
View directory record Official record
Conditions
Intracerebral Haemorrhage, Intraventricular
Interventions
Pioglitazone 15mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

NCT00631007
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 4, 2026, 10:34 PM EDT
Withdrawn Phase 2 Interventional

Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI

NCT02585765
View directory record Official record
Conditions
Spinal Cord Injury, Pressure Ulcers
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

NCT00736099
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 82 Years
Enrollment
2,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Chula Vista, California • Spring Valley, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 4, 2026, 10:34 PM EDT
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Pioglitazone for the Treatment of Alcohol Use Disorder

NCT03864146
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Brief Behavioral Compliance Enhancement Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Long Beach, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 4 Interventional

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study

NCT04473274
View directory record Official record
Conditions
Coronavirus Infection, Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Samaritan Health Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease

NCT02697617
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 4, 2026, 10:34 PM EDT
Recruiting Phase 2 Interventional

Bioenergetic Effect of Pioglitazone in CLD-PH

NCT06336798
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions
Pioglitazone 30mg, Placebo, Labs
Drug · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

NCT00353587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MBX-102, Placebo, Actos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Jonesboro, Arkansas • Buena Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)

NCT00919555
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pioglitazone and Tretinoin, Tretinoin and Pioglitazone HCL, Placebo
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 4, 2026, 10:34 PM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

NCT00280865
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tesaglitazar, Pioglitazone, Dietary and Lifestyle Modification Counseling
Drug · Behavioral
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
90
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2006 · Synced Oct 4, 2026, 10:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pioglitazone to Treat Opioid Withdrawal Symptoms

NCT01517165
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 4 Interventional

Pioglitazone Incretin Study

NCT00656864
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

NCT00063622
View directory record Official record
Conditions
Liver Diseases
Interventions
Pioglitazone, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 4, 2026, 10:34 PM EDT
Withdrawn Phase 2 Interventional

Study the Relationship Between Obesity and Hepatitis C Replication

NCT01157975
View directory record Official record
Conditions
Hepatitis C
Interventions
Pioglitazone, Prednisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

NCT01151670
View directory record Official record
Conditions
Brain Neoplasms, Malignant, Brain Neoplasms, Benign, Malignant Meningioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Pioglitazone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 4, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 4, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03457597
View directory record Official record
Conditions
Healthy
Interventions
Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 4, 2026, 10:34 PM EDT